x
ServiziMenu principaleHome
You are here: Home > Events > Past events > 2016 > 3rd ESO-ESMO Breast Cancer in Young Women International Conference (BCY3)
Print

3rd ESO-ESMO Breast Cancer in Young Women International Conference (BCY3)

12 ESCO credits

10.11.2016  -  12.11.2016

Lugano, Switzerland

CONFERENCE

Breast cancer

Description



Chair:
 O. Pagani, CH

Scientific Committe: H. Azim Jr, BE - F. Cardoso, PT - R. Dent, SG - S. Loibl, DE - S. Paluch-Shimon, IL - A.H. Partridge, US - F.A. Peccatori, IT
 

Breast cancer in young women is a complex disease, occurring when these women are at the peak of their reproductive years, family life and careers. Being a somewhat rare disease the optimal management of these patients is based on scientific data derived from clinical trials mostly conducted on older women. Many aspects of breast cancer in young women are therefore poorly understood (e.g. etiology and biology among others) and research is much needed in this field. In addition, young women have many years ahead of them to suffer the long-term effects of treatment or the consequences of recurrent disease. This third conference is a new opportunity for the latest updates on this field and a platform for generating future research concepts and collaborations. It will cover epidemiology, molecular biology, genetics, pathology, surgery, radiotherapy, systemic therapy, survivorship issues (e.g. fertility preservation, psychosocial needs) in young women with breast cancer.
It will also include a Consensus Session that will form the basis for a Consensus Guidelines manuscript to be published after the Conference.


LEARNING OBJECTIVES
• In depth learning and update of the scientific and clinical aspects of breast cancer in young women
• Highlight the importance of multi-disciplinary management and discuss difficult clinical cases
• Focus on clinical research priorities and future perspectives, involving patients’ advocates in setting the agenda
• Participate in the discussion of consensus guidelines


MAIN TOPICS
• Epidemiology of early and advanced disease

• Biology
• Hereditary breast cancer
• Diagnostic tools and challenges
• Loco-regional therapy
• Systemic therapy
• Psychosocial aspects and survivorship


The Conference is an ESO-ESMO joint event.
Furthermore, the BCY3 guidelines will be developed by ESO and ESMO

       
 
       
       
Held under the patronage of      
       
   

General information

ORGANISING SECRETARIAT
Organisation and Programme
Francesca Marangoni (1)
email: fmarangoni@eso.net
phone: +39 02 85464525

Registrations and Abstracts
Elena Fiore (1)
email: efiore@eso.net
phone: +39 02 85464529

Sponsorship and travel grants
Luis Carvalho (2)
email: lcarvalho@eso.net
phone: +41 91 8200958

(1) European School of Oncology, Via Turati 29, 20123 Milan, Italy
(2) European School of Oncology, Piazza Indipendenza 2, 6500 Bellinzona, Switzerland


VENUE
Palazzo dei Congressi Lugano
Piazza Indipendenza 4
6900 Lugano
Switzerland
Website: www.luganoconventions.com/en/13


OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.


INSURANCE
The organisers bear no responsibility for ontoward events in relation to the participation in the Conference. Participants are advised to take out their own personal and travel insurance coverage.


ABSTRACT BOOK
The abstract book has been published as a supplement to The Breast and will contain abstracts of the invited lecturers and those submitted by the participants that have been accepted for oral or poster presentation or for publication only. The best abstracts has been selected for oral presentation, plus in every category an outstanding abstract has been indicated. The abstracts deadline was 26 June 2016.


CME ACCREDITATION CERTIFICATES
Participants will be issued a certificate of attendance.
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value.
The event is designated for a maximum of 12 European CME credits (ECMEC).
Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
The programme was furthermore awarded with 11 cat. 1 ESMO-MORA points.


SPONSORSHIP OPPORTUNITIES
For further information, please contact Luis Carvalho (lcarvalho@eso.net)


WI-FI ACCESS
Free Wi-Fi internet access in all areas of the BCY3 venue is available.
WLAN SSID: PalazzoCongressi
Password: P4LC2k15LgN


FILMING, AUDIOITAPING AND PHOTOGRAPHS
Please note that capturing contents of the sessions is prohibited.


REGISTRATION DESKS, OPENING HOURS
Thursday, 10 November 10:00 - 18:30
Friday, 11 November 8:00 - 18:00
Saturday, 12 November 8:00 - 13.00


EXHIBITION, OPENING HOURS
Thursday, 10 November 12:00 - 18:00
Friday, 11 November 8:30 - 17:45
Saturday, 12 November 8:30 – 13.00


FACULTY AND PANEL MEMBERS
Members of the faculty are invited to refer to the Faculty Room (first floor).


TRAVEL GRANTS
Travel grants were made available on a competitive basis
ESO is particularly grateful to The Breast Cancer Research Foundation and Susan G. Komen for having provided grants to
support the participation of several participants.


BCY CONFERENCE AND CONSENSUS GUIDELINES
Breast Cancer in Young Women Conference (BCY1)
8-10 November 2012
The guidelines are published in The Breast 23 (2014) 209-220

2nd Breast Cancer in Young Women Conference (BCY2)
4-5 November 2014
The guidelines are published in The Breast 26 (2016) 87-99

3rd ESO-ESMO Breast Cancer in Young Women International Conference (BCY3)
10-12 November 2016
ESO is pleased to announce that the BCY3 guidelines will be developed jointly by ESO and ESMO and published simultaneously in The Breast and Annals of Oncology journals.


SPONSORS
ESO wishes to express its appreciation to the following sponsors for having granted their participation and support to BCY3:

Travel grants, support to the Conference and to the patient advocacy activities
 
 
   
               
                       
                       
Participating companies                      
                       
               
                       
       
               
                       



IMPORTANT DEADLINES
Late registration: 23 October 2016
On-site registration: after 23 October 2016




Faculty list


CHAIR
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH


SCIENTIFIC COMMITTEE

H.A. Azim Jr, Innate Pharma, Marseille, FR
F. Cardoso, Champalimaud Clinical Centre, Lisbon, PT
R. Dent, National Cancer Center and Duke-NUS, Singapore, SG
S. Loibl
, German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, DE
S. Paluch-Shimon, Sheba Medical Center, Ramat Gan, IL
A.H. Partridge, Dana-Farber Cancer Institute, Boston, US
F.A. Peccatori, European School of Oncology and Istituto Europeo di Oncologia, Milano, IT


FACULTY (as of October 2016)
O. Abulkhair, King Abdulaziz Medical City for National Guard, Riyadh, SA
S. Aebi, Luzerner Kantonsspital, Lucerne, CH
F. Amant, University Hospitals of Leuven, Leuven, BE
B.K. Arun, UT MD Anderson Cancer Center, Houston, US
R. Bender-Gàl, EuropaDonna Switzerland, Thun, CH
G. Bianchi Micheli, Breast Centre of the Italian Switzerland (CSSI), Lugano, CH
C. Canonica, Bellinzona and Valli Regional Hospital, Bellinzona, CH
M.J. Cardoso, Champalimaud Clinical Centre, Lisbon, PT
M. Conti Beltraminelli, Breast Centre of the Italian Switzerland (CSSI), Lugano, CH
D. Dizon
, Massachusetts General Hospital Cancer Center, Boston, US
T. Gagliardi, Aberdeen Royal Infirmary, Aberdeen, UK
K. Gelmon
, BC Cancer Agency, Vancouver, CA
O.D. Gentilini, San Raffaele Hospital, Milan, IT
L. Giordano, S. Giovanni Battista Hospital and Turin University, Turin, IT
N. Harbeck, University of Munich (LMU), Munich, DE
Y. Harder, Regional Hospital of Lugano, Lugano, CH

B. Kaufmann, Sheba Medical Center, Tel Hashomer, IL
A. Margulies
, EONS Education Working Group, Zurich, CH
V. Martin
, Institute of Pathology, Locarno, CH
F. Meani
, Breast Centre of the Italian Switzerland (CSSI), Lugano, CH
D. Meirow, Sheba Medical Center, Tel Hashomer, IL
J. Nunes, Hospital Beatriz Ângelo, Lisbon, PT
E. Paskett, The Ohio State University, Columbus, US
G. Pruneri
, European Institute of Oncology, Milan, IT
S. Raz Oren, Tel Aviv, IL
A. Richetti
, Oncologic Institute of the Italian Switzerland (IOSI), Bellinzona, CH
T. Ruhstaller, Kantonspital, St. Gallen, CH
H. Rundqvist, Karolinska Institute, Stockholm, SE
E. Senkus-Konefka
, Medical University of Gdansk, PL
T. Spanic
, EuropaDonna, Ljubljana, SI
F. Stiefel
, University Hospital Vaudois (CHUV), Lausanne, CH
M. Sutliff, Young Survival Coalition, New York, US
K. Syrjala
, Fred Hutchinson Cancer Research Center, Seattle, US
M. Taborelli, Oncologic Institute of the Italian Switzerland (IOSI), Bellinzona, CH
L. Travado, Champalimaud Cancer Center, Lisbon, PT
M.C. Valli, Breast Centre of the Italian Switzerland (CSSI), Lugano, CH
V.A. Vitale, Regional Hospital of Lugano, Lugano, CH
S. Zehbe, Bellinzona and Valli Regional Hospital, Bellinzona, CH


Programme

 

 10 November

     
OPENING SESSION
Chair: O. Pagani, CH 
 12:00   Welcome by Cantonal Authorities:
The State Councilor Beltraminelli and The Honourable Tricarico

12:15   KEYNOTE 1: Presentation by young patient
R. Bender-Gàl, CH [Abs IN1]
12:30   KEYNOTE 2: Communication skills: anything different in young women?
F. Stiefel, CH
[Abs IN2]

NURSING SESSION (held in collaboration with EONS)
Chair: A. Margulies, CH
 13:00   Physical activity / Exercise and cancer
H. Rundqvist, SE 
[Abs IN3]

SESSION 1: Tumor biology
Chairs: V. Martin, CH - G. Pruneri, IT
14:00   Age and tumor biology
H.A. Azim Jr, FR
[Abs IN5]

SESSION 2: Diagnostic tools
Chairs: V.A. Vitale, CH - S. Zehbe, CH
14:20   Any future for breast cancer screening in young women?
L. Giordano, IT
[Abs IN6]

14:40   New diagnostic tools: can they improve early diagnosis in young women?
T. Gagliardi, UK
[Abs IN7]

15:00   Discussion
 15:15   Coffee break
SESSION 3: Familial and hereditary breast cancer
Chairs: M. Taborelli, CH - F. Stiefel, CH
 15:45   Establishing a program for young women at high risk for breast cancer
B.K. Arun, US
 16:05   Loco-regional management of hereditary breast cancer: opportunities against timing?
M.J. Cardoso, PT
[Abs IN9]

 16:25   Systemic therapies in BRCA+ breast cancer what's new?
S. Paluch-Shimon, IL
 16:45   Fertility preservation techniques and preimplantation genetic diagnosis for mutation carriers: ready for prime time?
D. Meirow, IL
 17:05   Addressing familial and hereditary breast cancer in different cultural environments -
The Saudi Arabia experience

O. Abulkhair, SA
[Abs IN12]

 17:25   Discussion
 17:45   Side effects and adherence to adjuvant therapies: any impact on outcome?
B. Kaufmann, IL

 18:00
  Welcome cocktail
     

 11 November

     
SESSION 4: Loco-regional therapy
Chairs: Y. Harder, CH - M.C. Valli,CH
    The loco-regional multidisciplinary management:
8:30   The surgical perspective
O. Gentilini, IT
8:50   The radiation oncologist perspective
E. Senkus-Konefka, PL
[Abs IN15]

9:10   When and how to reconstruct considering long-term effects
M.J. Cardoso, PT
[Abs IN16]

9:30   Discussion
SESSION 5: Systemic therapies in early breast cancer
Chair: S. Aebi, CH
9:45   Any news in early breast cancer (EBC)?
A.H. Partridge, US
[Abs IN17]

10:05   Controversies in routine clinical management and research priorities
S. Loibl, DE
10:25   Young women with breast cancer in far East: anything different?
R. Dent, SG [Abs IN13]

10:45   Discussion
 11:00   Coffee break
SESSION 6: Fertility and pregnancy
Chairs: G. Bianchi Micheli, CH - S. Loibl, DE
 11:30   Pregnancy during breast cancer
F. Amant, BE
[Abs IN20]
11:50   Sexual life after breast cancer
D. Dizon, US
[Abs IN21]

12:10   Pregnancy after breast cancer 
F.A. Peccatori, IT
[Abs IN22]

12:25   The patient’s perspective
L. Gardel, CH
12:35   Discussion
12:45   Lunch and poster session
SESSION 7: Survivorship and quality of life issues
Chairs: M. Conti Beltraminelli, CH - E. Paskett, US
 13:45   Survivorship issues
S. Raz Oren, IL 
[Abs IN24]

 14:05   Lifestyle changes and prevention
K. Gelmon, CA
[Abs IN25]

 14:25   Psycho-oncology issues
L. Travado, PT
[Abs IN26]

 14:45   Managing daily life while having breast cancer
J. Nunes, PT
[Abs IN27]

 15:05   Information in the new media world
K. Syrjala, US
[Abs IN28]

 15:25   Discussion
 15:40   Coffee break
SESSION 8: Advanced breast cancer
Chairs: A. Richetti, CH - T. Ruhstaller, CH
 16:10   Any news in ABC?
F. Cardoso, PT

 16:30   Controversies in routine clinical management and research priorities
N. Harbeck, DE 
[Abs IN30]

 16:50   Discussion
 17:00   Patient advocate session and workshops
Chair:
T. Spanic, SI - M. Sutliff, US [Abs IN32]
     

 

 12 November

     
SESSION 9: Case discussion
8:30   Case Discussion - early breast cancer
Chairs: F. Meani, CH - E. Senkus-Konefka, PL
 9:15   Case Discussion - advanced breast cancer
Chairs:
O. Pagani, CH - A.H. Partridge, US
10:00   Best abstract presentation
Chair: C. Canonica, CH
Advocacy training program targeting low-income young women affected by breast cancer improves knowledge and enhances outreach efforts
A. Ahlum Hanson, US 
[Abs IN34]

10:10   Coffee break
 10:40   Summary statement on behalf of the Young Women Advocates
SESSION 10: Breast Cancer in Young Women International Conference Statements (10:50)
Panelists: O. Abulkhair, SA - F. Cardoso, PT - M.J. Cardoso, PT - K. Gelmon, CA - O. Gentilini, IT - N. Harbeck, DE - A. Margulies, CH - O. Pagani, CH - S. Paluch-Shimon, IL - A. H. Partridge, US - F.A. Peccatori, IT - G. Pruneri, IT - E. Senkus-Konefka, PL - T. Spanic, SI - M. Sutliff, US - L. Travado, PT
 13:00   Closure
     

A/V RECORDING DURING THE CONFERENCE IS PROHIBITED
POSTER SESSION

A prefix has been added to the abstract number to identify the type of presentation or acceptance:
IN: Abstracts submitted by the invited speakers.
OR: Abstract accepted for oral presentation.
BP: Abstracts identified as best posters.
PO: Abstracts accepted for poster presentations.
PR: Abstracts accepted for inclusion in the abstract book.

OR34
Advocacy training program targeting low-income young women affected by breast cancer improves knowledge and enhances outreach efforts. Ahlum Hanson Arin, US
BP35 Familial breast cancer risk assessment: a nurse led approach. Hanhauser Yvonne, IR
BP45 Oncology physicians’ perspectives on practices and barriers to fertility preservation and the feasibility of a prospective study of pregnancy after breast cancer. Rosenberg Shoshana, US
BP83 YSC’s shady pink elephant end of life series. Merschdorf Jennifer, US
PO36 Lymphedema prevention in young breast cancer patients. Kuznecovs Sergejs, LV
PO37 YSC’s research agenda on breast cancer in young women: what now? Merschdorf Jennifer, US
PO38 Young breast cancer survivors as advocates: YSC’s RISE program. Merschdorf Jennifer, US
PR39 Can art play a role in medicine and survivorship? Bianca Mueseler Shirley, DE
PR40 Waiting time for breast cancer treatment: does it affect survival? Gupta Nayan, IN
PR41 Reducing financial and manpower problems to provide palliative care: experience of an Indian NGO. Manna Aditya, IN
PR42 Difficulties in providing palliative care for terminal breast cancer in rural India (West Bengal) - experience of an NGO. Manna Aditya, IN
PR43 Breast cancer in women in Ghana - the dire need for National Breast Management Guidelines. Okpala Amalachukwu Michael, UK
PO46 Breast cancer in young women - special attention needed in developing countries. Agrawal Sanjit, IN
PR47 Demographic profile and outcome of pregnancy associated breast cancer (PABC) patients in a tertiary care center in India. Bajpai Jyoti, IN
PO49 Survival outcomes in Egyptian young patients with breast cancer: single institute experience. Kamal Jomaa Mona, EG
PO50 Pregnancy outcome after endocrine therapy (ET) in hormone receptor (HR)-positive young patients with breast cancer aged 35 years or younger in Japan. Kataoka Akemi, JP
PO51 Breast cancer in their twenties: clinical outcome of very young breast cancer patients in a cancer hospital in Pakistan. Khan Samreen, PK
PO52 Patterns of relapse in young (less than 35 years old) breast cancer patients: single centre experience from developing country. Khullar Pooja, IN
PO53 Breast cancer subtypes in  young adult women in Georgia. Kiladze Ivane, GE
PO54 The value of hormone serum concentration to predict the gonadotoxic effect of chemotherapy and the efficacy of LHRH analogs as a strategy to reduce treatment-related premature ovarian failure in breast cancer. Lambertini Matteo, IT
PR55 Predictors of higher mortality in younger breast cancer patients: a population-based study. Martinez Maria Elena, US
PR56 Patterns of presentation and survival in young breast cancer females - a single institute experience, Mehmood Tahir, PK
PR57 Clinical outcome of triple negative breast cancer patients among different age groups: a comparative study, Mehmood Tahir, PK
PR58 Worst prognostic factors in young women with breast cancer. Mehmood Tahir, PK
PO60 How accurate is mammography and MRI screening in women at increased risk and without a  BRCA1/2 mutation? Phi Xuan Anh, NL
PO62 Imaging of breast cancer in young women - how successful are we in diagnosing tumours in the general population? Steyerova Petra, CZ
PO63 Clinicopathological characteristics and prognosis in very young womeN (≤35 years old) with breast cancer. Utsumi Toshiaki, JP
PO64 BRCA mutations in young women - overview of a tertiary Breast Unit. Volovat Simona Ruxandra    RO
PO65 Breast cancer in young women - An institutional study from India. Yadav Budhi Singh, IN
PO66 Clinico-pathologic features of breast cancer in young Pakistani women. Zeeshan Sana, PK
PR67 Triple-negative breast cancer with or without BRCA mutation: looking at the future. Ballatore Zelmira, IT
PR69 Surgical treatment of hereditary breast cancer: a new one-step multidisciplinary surgical procedure. Fachinetti Anna, IT
PR70 Monocentric retrospective analysis of primary breast cancer tumor in patients with BRCA mutation and evaluation of TILs (Tumor Infiltrating Lymphocytes) and ratio N/L (Neutrophiles/Lymphocytes). Gallerani Elisa, IT
PR71 Validation of nomograms to predict the risk of positive margins following breast-conservative surgery in a young North African Tunisian breast cancer population. Hidar Samir, TN
PR72 Pharmacogenetic personalised treatment of breast cancer in young patients. Ibragimov Jamshid, UZ
PR73 A 34 year old female with breast cancer and multiple endocrine neoplasia type 1 (MEN 1): a case report, Inic Zorka, RS
PR74 Effect of neoadjuvant chemotherapy in Albanian young women with breast cancer, Kozma Elvisa, AL
PR76 Re-visiting breast cancer and cultural practices towards intervention. Menang Ngwang, CM
PR77 An overview of BRCA variants in young breast cancer patients from Romania. Negura Lucian, RO
PR78 Oncological and cosmetic superiority of intraoperative ultrasound (IOUS) in breast conservation surgery (BCS): experience from a developing country. Saha Shivangi, IN
PR79 Prospects of fine needle aspiration biopsy of breast lesions from a tertiary care center of central India: data from an untouched region. Singh Sandeep, IN
PR80 Lipofilling of the axilla to reduce secondary lymphedema after axillary lymph node dissection. Vandermeeren Liesbeth, BE
PR81 Prognostic value of immunohistochemical markers RE, RP, Her2 /neu in breast cancer in young women. Zakirova Lolakhon, UZ
PR82 A new approach to the treatment of resistant breast cancer. Zakirova Lolakhon, UZ
PO84 Knowledge of breast cancer among newly diagnosed young female clients at Komfo Anokye Teaching Hospital, Ghana. Asoogo Comfort, GH
PR85 “The unsaid”: an editorial project of Narrative Medicine in the Breast Unit of Pisa. Camilleri Valeria, IT
PO86 Young breast cancer patients: contraceptive methods used at diagnosis and frequency of unintended pregnancy during the first year after diagnosis. Güth Uwe, CH
PO87 Exploring how women make decisions on neoadjuvant systemic therapy (NAST) for operable breast cancer. Herrmann Anne, AU
PO88 Quality of life in long-term breast cancer survivors - evidence from South. India, Katpattil Sabin, IN
PO89 Matrimonial risk factors in young women with breast cancer. Kuznecova Galina, LV
PO90 Attitudes of local advocacy groups/allied health staffs towards young women with breast cancer: a survey. Lee Guek Eng, SG
PO91 Pregnancy and adoption after treatment for breast cancer in young survivors. Naughton Michelle, US
PO92 A cross-sectional study on cognitive impairment in Mexican breast cancer survivors. Platas Alejandra, MX
PR93  Awareness and attitudes regarding breast cancer and breast self-examination among female university students - An exploration. Asmin Sha, IN
PO94
EORTC BR23 questionnaire: acceptability in measuring quality of life in breast cancer patients in India. Srivastava Anurag, IN
PO95 A focus group study of unmet needs in Mexican young women with breast cancer. Villarreal-Garza Cynthia, MX
PR96 Anxiety/depression in young women with nonmetastatic breast cancer in Durres, Albania. Luzi Manjola, AL
PR97 Awareness among women regarding warning signs and effective screening methods in breast cancer. Ashna Siddique, IN
PR98 Predictors of depression among breast cancer patients in Nepal. Sharma Abha, NP

BEST ABSTRACTS AUTHORS
OR: Ahlum Hanson Arin, US
BP: Hanhauser Yvonne, IR
BP: Merschdorf Jennifer, US
BP: Rosenberg Shoshana, US

DISCAIMER

No responsibility is assumed by the organisers for any injury and/or damage to persons or propriety as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Organisers recommend that independent verification of diagnosis, therapies and dosages should be made. Every effort has been made to faithfully reproduce the materials as submitted. However, no responsibility is assumed by the organisers for any omissions or misprints.



PO53    Breast cancer subtypes in  young adult women in Georgia. Kiladze Ivane, GE
PO54    The value of hormone serum concentration to predict the gonadotoxic         effect of chemotherapy and the efficacy of LHRH analogs as a strategy to         reduce treatment-related premature ovarian failure in breast cancer.        Lambertini Matteo, IT
PR55    Predictors of higher mortality in younger breast cancer patients: a             population-based study. Martinez Maria Elena, US
PR56    Patterns of presentation and survival in young breast cancer females – a         single institute experience, Mehmood Tahir, PK
PR57    Clinical outcome of triple negative breast cancer patients among             different age groups: a comparative study, Mehmood Tahir, PK
PR58    Worst prognostic factors in young women with breast cancer.            Mehmood Tahir, PK
PO60    How accurate is mammography and MRI screening in women at             increased risk and without a  BRCA1/2 mutation? Phi Xuan Anh, NL
PO62    Imaging of breast cancer in young women - how successful are we in         diagnosing tumours in the general population? Steyerova Petra, CZ
PO63    Clinicopathological characteristics and prognosis in very young women         (≤35 years old) with breast cancer. Utsumi Toshiaki, JP
PO64    BRCA mutations in young women - overview of a tertiary Breast Unit        Volovat Simona Ruxandra    RO
PO65    Breast cancer in young women - An institutional study from India.   Yadav Budhi Singh, IN
PO66    Clinico-pathologic features of breast cancer in young Pakistani women.        Zeeshan Sana, PK
PR67    Triple-negative breast cancer with or without BRCA mutation: looking at         the future. Ballatore Zelmira, IT
PR69    Surgical treatment of hereditary breast cancer: a new one-step             multidisciplinary surgical procedure. Fachinetti Anna, IT
PR70    Monocentric retrospective analysis of primary breast cancer tumor in         patients with BRCA mutation and evaluation of TILs (Tumor Infiltrating         Lymphocytes) and ratio N/L (Neutrophiles/Lymphocytes). Gallerani Elisa, IT
PR71    Validation of nomograms to predict the risk of positive margins following     breast-conservative surgery in a young North African Tunisian breast         cancer population. Hidar Samir, TN
PR72    Pharmacogenetic personalised treatment of breast cancer in young         patients. Ibragimov Jamshid, UZ
PR73    A 34 year old female with breast cancer and multiple endocrine             neoplasia type 1 (MEN 1): a case report, Inic Zorka, RS
PR74    Effect of neoadjuvant chemotherapy in Albanian young women with         breast cancer, Kozma Elvisa, AL
PR76    Re-visiting breast cancer and cultural practices towards intervention.         Menang Ngwang, CM.

Abstract


ABSTRACT SUBMISSION

THE DEADLINE FOR SUBMISSION HAS PASSED (26 JUNE 2016)

 
Abstracts will be assessed for oral and poster presentation at the conference, or for publication only in the BCY3 Abstract Book which will be published as a supplement of The Breast.
     
  The best abstract will be selected for a 5-minute oral presentation on Saturday, 12 November and for poster presentation on Friday, 11 November. Free registration will be granted to the first author of the selected abstract.
  Further abstracts will be selected for poster presentation on Friday, 11 November.
     
    Participants were invited to submit an abstract on breast cancer in young women, in one of the following categories:
     
  Advocacy (i.e. lobbying and activities of the advocacy groups)
  Basic-Translational-Clinical Research
  Psycho-social care (including nursing, psycho-social aspects, job discrimination and fertility issues, etc.)
     
Instructions:
     
  The abstract should be limited to 2800 characters
  The title should be in lower case letters
  Each author should be listed within the online system
  The corresponding author should be indicated (first author = corresponding author and presenter)
  The authors’ affiliations will be requested
  The complete details with e-mail address of the corresponding author (first author and presenter) must be provided. The corresponding author will receive an acknowledgement of receipt and all subsequent communications by e-mail.
  For the abstract accepted for presentation, the first author will be the presenting author and is requested to register and participate in the Conference.
  It is the responsibility of the corresponding author to ascertain whether all authors are aware of the content of the abstract before submission is made.
     
The acknowledgement of receipt of the abstract will immediately follow the submission. The outcome will be notified by 22 July to the first author who will be required to register to the Conference (early registration deadline: 31 July).

 

Follow us